Catalent strengthens leadership position in Asia-Pacific
Company announces key appointments and a new sales office in Korea.
Catalent Pharma Solutions has announced two key appointments and the opening of a new sales office in Korea to support the company’s continued investment and strategic growth plans in the Asia Pacific region.
Howard Kim has joined the company in the role of Director of Business Development in Korea, and will work between Catalent’s new sales office in Seoul, South Korea, and the company’s Somerset, NJ, headquarters. Mr Kim will manage business development activities across all of Catalent’s business units in the expanding Korean market.
Prior to joining Catalent, Mr Kim was responsible for developing businesses for Korean pharmaceutical companies in the US and in Europe. He has also worked for Novartis, Sandoz, Schering-Plough, Wyeth, and Merck in the areas of product supply and planning.
In a second appointment, Erin Vlack has been promoted to Manager of the company’s new Clinical Supply Services site in Kakegawa, Japan, which is to provide secondary packaging, labeling, storage and distribution capabilities locally.
In this role, Ms Vlack will establish and lead the site’s clinical supply operations, driving the business strategy, achieving necessary regulatory standards, meeting on-time delivery, quality, and efficiency targets, and establishing safe working practices within the site’s cGMP environment.
Ms Vlack has 12 years of progressive project management experience, a decade of which spans Japanese business strategy, contract manufacturing, pharmaceutical and clinical trial logistics, and supply and depot management. Since joining Catalent in April 2015, Ms Vlack has held the role of Project Manager at the company’s Morrisville, North Carolina facility in the US. Prior to this she lived, studied and worked in and around Japan for over 20 years.
Catalent has offered clinical supply services in the region since 2005, and within the past 3 years has made significant capital investments totaling more than $10 million with additional personnel to expand its overall Asia-Pacific footprint to meet growing customer demand. Today, the company’s network spans nine audited depots and three fully owned and operated clinical packaging facilities in China, Singapore, and Japan when it opens for business later this year. Available services include primary and secondary packaging, demand led supply services, clinical storage, cold chain services, global distribution, comparator sourcing, project management, clinical supply management, regulatory consulting, and returns and destruction.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance